3 May 2018 - The US FDA has granted fast track and breakthrough therapy designations to rAd-IFN/Syn3.
Ferring Pharmaceuticals today announced the signing of an agreement giving the company the option to secure global commercialisation rights to nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), a novel gene therapy being developed by FKD Therapies Oy as a treatment for patients with high-grade non-muscle invasive bladder cancer, who are unresponsive to Bacillus Calmette-Guérin therapy.
This option is exercisable on marketing approval from the US FDA. Ferring will create a new US oncology division with the specialist knowledge and presence to introduce novel advanced therapies to the market.